Q-Check Pharmaceuticals — Care beyond Healthcare

Managing Cholesterol Complexity in Modern Cardiology — ApoB, Lp(a), and Triglycerides

Statins transformed cardiovascular medicine. But residual cardiovascular risk — the events that occur despite optimal statin therapy — has driven intensive investigation into the targets that statins do not address. The result is a new multi-target paradigm for lipid management that moves beyond LDL-C as the sole objective.

ApoB: The Emerging Primary Target

ESC 2024 Prevention Guidelines are progressively shifting toward ApoB as the primary lipid management target. Unlike LDL-C, which measures cholesterol content in LDL particles, ApoB directly counts all atherogenic lipoprotein particles — including small dense LDL particles that are particularly pro-atherogenic but may not raise calculated LDL-C significantly.

Clinical evidence: ApoB predicts CVD risk independently of LDL-C
Practical threshold: ApoB <55 mg/dL for very high-risk patients

Lp(a): The Undertreated Risk Factor

Lipoprotein(a) — elevated in approximately 20% of the population — represents one of the most significant undertreated cardiovascular risk factors. APO(a)-targeting antisense agents are currently in phase 2 trials, with expected approval in 2026, offering the first specific pharmacological approach to Lp(a) reduction.

The Lipid Cascade Therapy Algorithm

Step 1: High-dose statin + ezetimibe (dual mechanism, complementary efficacy)
Step 2: Add PCSK9 inhibitor if target not achieved (inclisiran — twice-yearly dosing improves adherence)
Step 3: Add inclisiran for sustained, durable LDL-C reduction

Triglyceride Management

The REDUCE-IT trial established icosapent ethyl (EPA) as a cardiovascular risk reducer in hypertriglyceridaemic patients beyond LDL-C lowering. Combined with fenofibrate for comprehensive triglyceride management, this approach addresses a dimension of residual risk that statins alone do not resolve.

Research Sources